ISTH 2026 Supported Symposia & Presentation Theaters
​

Our Congress program offers several time slots for informing ISTH 2026 participants about the latest research, product developments, and other scientific activities. Supported Symposia are scientific or educational in nature, offering a platform for in-depth presentations and discussions. Meanwhile, Presentation Theaters are designed to provide industry partners with an opportunity to showcase new research findings, share product information, offer live demonstrations, or raise disease awareness among ISTH 2026 Congress delegates. We hope you will take advantage of these valuable opportunities to engage with the global hemostasis and thrombosis community and highlight your latest innovations.​

 

See below for session titles, dates and times.

 

Saturday, July 11, 11:30 – 12:45  |  Supported Symposia​

• The ITP Conversation: Today’s Practice, Tomorrow’s Potential (Novartis) 
  Room W01-02

• ​When Conventional Treatment Is Not Enough: Escalating Care in PE and DVT – A Multidisciplinary Perspective (Inari, now part of Stryker) 
  Room W07-08

​

Sunday, July 12, 12:15-13:30  |  Supported Symposia

• The Future of Hemostasis Rebalancing (Sanofi)
  Room E03-04

• ☆ Starting Strong, Staying Strong: Evidence for Sustained Protection for a Life with Haemophilia A (Roche and Chugai)
  Room S04

• ​Von Willebrand Disease: A Holistic Approach (CSL)
  Room W01-02

• Evolving Clinical Pathways in iTTP: Emerging Treatment Approaches and Managing Complex Cases (Sanofi)
  Room W03-04

• Closer to Nature. Designed for Protection. Scientific symposium on ULTRA 8, an investigational FVIII in development (Octapharma)
  Room W05-06

• Assessing the Potential of Factor XIa Inhibition for Secondary Stroke Prevention: Supporting Our Cross-Specialty Colleagues in Improving Patient Outcomes (PeerVoice)
  Room W07-08

 

Sunday, July 12, 13:45 - 14:30  |  Presentation Theaters

• High-Sensitivity D-Dimer in VTE Exclusion: Clinical Decision Rules and Global Harmonization (Werfen)
  Presentation Theater 2

• ​HEMGENIX® in Practice: Real-World Strategies and Learnings (CSL)
  Presentation Theater 3​

• The Paediatric VWD Journey: Burden of Disease and Treatment Realities (Takeda)
  Presentation Theater 4

 

Monday, July 13, 12:15 - 13:30  | Supported Symposia

• Shaping the Future of Haemophilia A: Redefining Clinical Outcomes (Swedish Orphan Biovitrum [Sobi])
  Room E03-04

• Personalised Future: Gene Therapy and Patient-Reported Outcomes in Haemophilia (CSL)
  Room E05-06

• From Immune Mechanisms to Clinical Practice: Rethinking Autoimmune Cytopenias (Sanofi)
  Room W01-02

• From Evidence to Individualisation: Redefining Prophylaxis in von Willebrand Disease (Octapharma)
  Room W03-04

• Prophylaxis across the axis: Key considerations for patient care in VWD and cTTP (Takeda)
  Room W05-06

• Haemophilia Beyond the Basics: From Complex Scenarios to Confident Care (Pfizer)
  Room W07-08

 

Monday, July 13, 13:45 – 14:30  |  Presentation Theaters

• The Impact of an Ultra-Long Half-Life (UHL) Factor: Real-World Insights With ALTUVIIIO® (Sanofi)
  Presentation Theater 1

• Everyday Protection with Concizumab (Alhemo®): Redefining Precision and Control in Haemophilia B (Novo Nordisk Healthcare AG)
  Presentation Theater 2

• ​A Decade of IDELVION®: From Evidence to Confidence (CSL)
  Room Presentation Theater 3

• From HIT IgG to ADAMTS-13 activity: High-Sensitivity Chemiluminescence on a routine coagulation analyzer (Sysmex Europe SE)
  Presentation Theater 4

 

Tuesday, July 14, 12:15 – 13:30  |  Supported Symposia

• Same Goals, New Paths: Evaluating today’s haemostatic therapies (Octapharma)
  Room E03-04

• Clinical Decision-Making in Hereditary Factor X Deficiency: Tailoring Care for Women, Girls, and Pediatric Patients (Kedrion Biopharma)
  Room W01-02

• From Molecular Mimicry to Patient Mastery: The New Normal? (Novo Nordisk Healthcare AG)
  Room W03-04

• Challenging the status quo: towards better patients' outcomes in VWD (LFB BIOMEDICAMENTS)
  Room W07-08

 

Tuesday, July 14, 13:45 – 14:30  |  Presentation Theater

• ​​​Plasminogen Deficiency Type 1: A Rare Multisystem Disease with Lifelong Clinical Consequences (Kedrion Biopharma)
  Presentation Theater 3

• “Remodelling the perioperative pathway for patients with haemophilia with inhibitors: a case based discussion”- AN INTERACTIVE DEBATE (LFB BIOMEDICAMENTS)
  Presentation Theater 4

 

☆ = Promotional bundle partners​